Company's expanding IP estate is led by multiple pending applications in peptide and biologic delivery, alongside advanced drug delivery, opioid-sparing pain management, pancreatic oncology, regenerative medicine and smart wound care
MEQUON, Wis., July 15, 2026 /PRNewswire/ -- Vector Science & Therapeutics, Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced the expansion of its intellectual property portfolio to 15 patent applications developed and filed over approximately the past two years, establishing a broad technology estate centered on one of medicine's most persistent challenges: delivering therapeutic agents — including peptides and other biologics that are frequently difficult to administer outside the gastrointestinal tract — to the right tissue, at the right concentration, for the appropriate duration of treatment.
Rather than focusing on a single drug, device or disease indication, Vector's intellectual property strategy has been built around a portfolio of interconnected therapeutic delivery technologies. The Company's patent applications encompass non-invasive, minimally invasive and locoregional systems intended to overcome biological, anatomical and patient-compliance barriers that can limit conventional pharmaceutical administration.
"We believe many promising therapeutic agents are constrained not simply by the molecule, but by the limitations of how that molecule reaches its intended target," said Tom Bachinski, Chief Technology Officer of Vector Science & Therapeutics. "Our intellectual property strategy is focused on the delivery problem. We are developing multiple technologies designed to move therapeutics across biological barriers, concentrate treatment at difficult-to-reach tissue and reduce unnecessary systemic exposure."
A Platform-Based Intellectual Property Strategy
Vector's patent portfolio encompasses a range of technologies that share a common objective: precision therapeutic delivery.
The Company's intellectual property includes technologies involving multi-route peptide and biologic delivery, advanced transdermal delivery, electrically assisted deep-tissue transport, interferential-hybrid iontophoresis, localized catheter delivery, lyophilized pharmaceutical formulations and point-of-care reconstitution, electrostatic spray administration, magnetic field-assisted delivery, microneedle and intratumoral systems, nanoparticle-enabled therapeutic transport, and sensor-guided treatment platforms.
Several applications combine multiple engineering and pharmaceutical disciplines within a single therapeutic system, integrating drug formulation, delivery hardware, electrical or electromagnetic energy, tissue sensing, feedback control and targeted release.